<DOC>
	<DOCNO>NCT00616811</DOCNO>
	<brief_summary>This clinical trial design provide additional information safety tolerability vildagliptin ( 50 mg daily ( qd ) ) sitagliptin ( 25 mg qd ) use patient type 2 diabetes mellitus ( T2DM ) severe renal insufficiency ( Glomerular filtration rate ( GFR ) &lt; 30 mL/min ) period 24 week .</brief_summary>
	<brief_title>Safety Tolerability Vildagliptin Versus Sitagliptin Patients With Type 2 Diabetes Severe Renal Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criterion History T2 DM Severe Renal Impairment Exclusion criterion Glucose ≥ 270 mg/dL ( ≥15 mmol/L ) Patients undergo method dialysis Treatment therapy sulfonylurea , TZDs , insulin , metiglinides</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Type 2 diabetes , vildagliptin</keyword>
</DOC>